Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan; 62(1):222-33.

View in: PubMed

subject areas

Adult
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
B-Lymphocytes
Double-Blind Method
Female
Humans
Immunologic Factors
Lupus Erythematosus, Systemic
Male
Quality of Life
Rituximab
Severity of Illness Index
Treatment Outcome

authors with profiles

Tammy Utset